Company Description or Summary

Amaro is a preclinical, platform company focused on the emerging field of extra-oral bitter taste receptors (TAS2R) as therapeutic targets. The therapeutic potential of TAS2R modulation has been suggested in a broad range of human conditions from longevity to immuno-metabolic disorders to modulation of the microbiome. Via acquisition, the company is capitalizing on ten years of preclinical and clinical experience in the development of disease modifying compounds targeting these GPCR receptors.